Citations

Showing 10 of 108104 citations.

Abstract A183: Blood-based genomic profiling of cell-free tumor DNA (ctDNA) in patients with biliary tract cancer
Kelley, Robin Kate , Kiedrowski, Lesli A. , Catenacci, Daniel V.T. , Mody, Kabir , Shroff, Rachna T. , Reyes, Stephanie , Maurer, Jordan R., Corcoran, Ryan B. , Fanta, Paul T. , Cusnir, Mike , Nagy, Becky, Morse, Michael A. , Tan, Benjamin, Javle, Milind , Zhu, Andrew X. , Goyal, Lipika , Parikh, Aparna R. , Lanman, Richard B.

Mayo Clinic

Molecular Cancer Therapeutics | August 17, 2018 | Volume: 17 | Issue: 1_Supplement | Pages: A183-A183

10.1158/1535-7163.targ-17-a183 Get It

Abstract Background: Targeted therapies are increasingly under evaluation in clinical trials for the treatment of biliary tract cancer (BTC), and cell-free tumor DNA assays are an emerging technology for the detection of actionable alterations. Methods: ctDNA analysis was performed in patients with BTC using the CLIA-certified Guardant360 liquid biopsy assay as part of routine clinical care. The assay screens up to 73 genes for single-nucleotide variants (SNVs), 23 for insertions or deletions (INDELs), 18 for copy number variations (CNVs), and 6 for fusions. Results: 855 samples were analyzed from 751 unique BTC patients. Median age was 64 years (range, 29-89), 53% were female, and 631 (84%) had at least one alteration in their first sample. In the 751 patients, the most common genes altered were TP53 (39%), KRAS (15%), PIK3CA (13%), ARID1A (13%), EGFR (11%), FGFR2 (11%), ERBB2 (11%), NF1 (10%), IDH1 (10%), APC (9%), BRAF (9%), MYC (8%), MET (7%), CCNE1 (7%), and FGFR1 (7%). Alterations in DNA damage response genes were also seen, including BRCA2 (6%), BRCA1 (5%), ATM (4%), and MLH1 (1%). The median number of alterations per sample was 3 (range, 0-40). In a clinically annotated dataset from the Massachusetts General Hospital Cancer Center, 112 samples were obtained from 61 unique patients. Among these, 52 (85%) had intrahepatic cholangiocarcinoma (ICC), 3 (5%) had extrahepatic cholangiocarcinoma, and 6 (10%) had gallbladder cancer. 20/61 (33%) patients were treated with targeted therapy. Among 20 patients with both ctDNA and tumor sequencing results, the targetable mutation was found in both ctDNA and tumor tissue in 7/20 (35%), solely in ctDNA in 1/20 (5%), and solely in tissue in 12/20 (60%) patients. The patient with the alteration detected solely in ctDNA had insufficient tissue for analysis; she was found to have an FGFR2 F276C mutation and benefited for 8.5 months from an FGFR inhibitor on a clinical trial. Of the 12 patients whose targetable mutation was not detected in plasma, 10 (83%) had an FGFR2 fusion, 1 had an INDEL in FGFR2 (Leu262_Ala266delinsAsp), and 1 had an FGFR3 splice site mutation. 15/20 (75%) patients treated with targeted therapy were followed with serial ctDNA analysis, and a potential resistance mechanism was identified in 5/15 (33%). All 5 patients had FGFR2-fusion positive ICC and developed mutations in the FGFR2 kinase domain as a potential resistance mechanism to FGFR inhibition, including the FGFR2 V564F gatekeeper mutation in 4/5 patients. Conclusions: In patients with BTC, ctDNA-based genomic profiling can detect alterations in IDH, FGFR, PIK3CA, ERBB2, BRAF, and MET. The technology is still evolving for the detection of FGFR2 fusions, which is hindered in capture-based methods in plasma by the large number of unique breakpoints and fusion partners. ctDNA analysis may also provide a noninvasive mechanism to study resistance to targeted therapy and clonal dynamics in BTC. Citation Format: Lipika Goyal, Robin Kate Kelley, Lesli Kiedrowski, Daniel Catenacci, Kabir Mody, Rachna Shroff, Aparna Parikh, Stephanie Reyes, Jordan R. Maurer, Ryan B. Corcoran, Paul Fanta, Mike Cusnir, Becky Nagy, Richard Lanman, Michael Morse, Benjamin Tan, Milind Javle, Andrew Zhu. Blood-based genomic profiling of cell-free tumor DNA (ctDNA) in patients with biliary tract cancer [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A183.
Abstract IA21: Immunomodulatory therapy of multiple myeloma with IAP antagonists
Chesi, Marta , Fooksman, David , Bergsagel, P. Leif

Mayo Clinic

Clinical Cancer Research | August 17, 2018 | Volume: 23 | Issue: 24_Supplement | Pages: IA21-IA21

10.1158/1557-3265.hemmal17-ia21 Get It

Abstract Multiple myeloma (MM) is a tumor of terminally differentiated plasma cells that underwent affinity maturation and class switch recombination processes in germinal centers before homing to the bone marrow (BM), where they secrete large amounts of monoclonal immunoglobulins, clinically detected as an M-spike by serum protein electrophoresis (SPEP). Clinical manifestations of MM also include renal impairment, anemia, and bone disease, the latter resulting from abnormal osteoclast activation, which highlights the complex crosstalk between MM cells and their BM microenvironment. Chromosomal translocations into the immunoglobulin loci are the primary oncogenic events in ~50% of MM cases and are thought to occur as a result of errors during somatic hypermutation or class switch recombination. The other half of MM is characterized by trisomies of odd-numbered chromosomes. Both of these genomic abnormalities are present in the premalignant phase of MM called MGUS, which progresses to MM at a rate of 1% per year. Progression events include mutations of genes in the RAS/MAPK pathways; chromosomal rearrangements of the MYC locus; and mutations, amplifications, or biallelic deletions of genes in the NFkB pathway. Among the latter, the most common are deletions of TRAF3 or cIAP1 and -2 (BIRC2 and -3) and amplification or translocations of NIK (Map3k14), all resulting in NIK stabilization, phosphorylation of IKKα, processing of p100 to p52, NFKB2 nuclear translocation, and activation of the noncanonical NFKB pathway. This can be induced in MM cell lines in vitro by treatment with SMAC mimetics or IAP antagonists (IAPa), which induce cIAP1 auto-ubiquitination and degradation. We postulated that the resulting constitutive activation of the noncanonical NFKB pathway would render MM cells independent on the BM-localized survival signals provided by BAFF and APRIL, leading to extramedullary dissemination. We tested this hypothesis in vivo by exposing Vk*MYC mice with BM-localized MM to the IAP antagonist LCL161 and monitoring disease progression. In the immunocompetent Vk*MYC transgenic mouse model MYC expression is sporadically induced in germinal center cells by AID-dependent somatic hypermutation, leading to progressive accumulation of monoclonal plasma cells restricted to the BM that can be monitored over time by SPEP and M-spike quantization, as is done clinically in MM patients. Through a very rigorous testing of drugs whose clinical activity in MM has been assessed in clinical trials, we have also validated Vk*MYC mice as a faithful model to predict drug activity in MM, with a positive predictive value of 73% and a negative predictive value of 92%. To our surprise, treatment of Vk*MYC mice with the IAPa LCL161 did not promote MM extramedullary dissemination as we predicted, but rather induced a significant reduction in M-spike levels, indicative of reduction of tumor burden. Based on these preclinical data, we conducted a phase 2 clinical trial of LCL161 in combination with cyclophosphamide in relapsed/refractory MM patients. Results from 25 patients enrolled in the study demonstrated a response in five patients (1CR, 1 VGPR, 2PR, 1MR) and a median PFS of 10 months. Consistent with in vitro data on MM cell lines, LCL161 treatment did not promote direct apoptosis of Vk*MYC cells but phagocytosis of live cells, detectable by intravital microscopy within four hours after treatment. While LCL161 treatment of BM-derived macrophages (MΦ) in vitro promoted the acquisition of an inflammatory phenotype, with increased expression of IL6, IL12, and CD86 that resembled activation with CD40 agonists, it did not increase their phagocytic ability. In contrast, exposure of MΦ to LCL161 treated tumor cells or to the conditioned medium collected after LCL161 treatment enhanced phagocytosis. We therefore performed gene expression analysis on MM cells collected from Vk*MYC mice and MM patients before and after LCL161 treatment and identified marked upregulation of NFKB target genes, as expected, but also a type-I interferon (IFN) signature. Interestingly, the presence of blocking antibody to the IFN receptor subunit 1 (aIFNAR1) during LCL161 treatment of tumor cells inhibited their phagocytosis in vitro, and pretreatment of Vk*MYC mice with aIFNAR antibody abrogated LCL161 activity in vivo. Pretreatment of Vk*MYC mice with liposomal clodronate, known to deplete phagocytic cells, also abrogated LCL161 activity, indicating that MΦ-dependent phagocytosis, stimulated by the LCL161 induced tumor cell autonomous IFN response, is required for the anti-MM effects of LCL161. LCL161 has been shown to promote T-cell function in vitro, but in our hand LCL161 retained full anti-MM activity in T-cell deficient mice. However, while ~15% of immunocompetent mice were cured by just two weeks of LCL161 treatment, none of the T-cell deficient mice were, indicating a role for T cells in preventing disease recurrence. Consistently, rechallenge of cured mice with specific MM tumors induced expansion of IFNγ-producing T cells, indicative of reactivation of immunologic memory. We were surprised by the hyporesponsiveness of T cells to LCL161 in vivo and attributed it to the high levels of expression of the coinhibitory molecule PD1 we noted on both CD4 and CD8 cells irrespective of treatment. We also detected high levels of PDL1 on most CD11b+ myeloid cells as well as on a fraction of MM cells, which increased following LCL161 treatment. We therefore sought to combine LCL161 with an antibody against PD1. Remarkably, the combination of LCL161 with aPD1 was curative in all the mice that completed the two-week treatment, and we are in the process of translating this discovery to the clinic by opening a new trial of LCL161 in combination with aPD1. Citation Format: Marta Chesi, David Fooksman, Peter Leif Bergsagel. Immunomodulatory therapy of multiple myeloma with IAP antagonists [abstract]. In: Proceedings of the Second AACR Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; May 6-9, 2017; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(24_Suppl):Abstract nr IA21.
Abstract PR08: Ubiquitin-specific protease 6 (USP6) oncogene confers sensitivity of Ewing sarcoma to interferon cytotoxicity
Henrich, Ian C. , Young, Rob, Quick, Laura , Wang, Xiaoke, Oliveira, André M. , Chou, Margaret M. , Wang, Xiaoke

Mayo Clinic

Clinical Cancer Research | August 17, 2018 | Volume: 24 | Issue: 2_Supplement | Pages: PR08-PR08

10.1158/1557-3265.sarcomas17-pr08 Get It

Abstract Our goal is to identify novel targeted therapies for Ewing sarcoma (ES). ES is a devastating malignancy that predominantly affects children and young adults. It is the second most common cancer of the bone, yet in contrast to many other malignancies, survival rates have not improved for decades. For patients with localized disease, no biomarkers exist to predict recurrence or response to chemotherapy. For those with metastatic disease, chemotherapy is largely ineffective, and 5-year survival rates have stagnated at approximately 20%. Thus, there is an urgent need to identify biomarkers that can predict recurrence and response to therapy, as well as identify novel targeted therapies to combat this lethal disease. USP6 is the key etiologic agent in several benign bone and soft tissue tumors (BSTTs), where its chromosomal translocation results in overexpression. USP6 encodes a deubiquitylating enzyme, and our prior studies identified the tyrosine kinase Jak1 as an essential substrate of USP6 during BSTT development. Jak1 levels are dramatically elevated in USP6-overexpressing cells, leading to phosphorylation and activation of STAT transcription factors. We recently discovered that USP6 is also highly expressed in multiple sarcomas, including ES. Since Jak1-STATs play a central in mediating response to interferon (IFN), we hypothesized that USP6 might cause dysregulated IFN signaling in ES. Microarray and RNA-sequencing analysis revealed that USP6 by itself induced an IFN-response gene signature, both in immortalized, patient-derived ES cells and in primary human ES tumors. USP6+ ES cells were found to be exquisitely sensitive to exogenous IFN compared to USP6- ES cells, with both prolonged and heightened STAT1 and STAT3 activation observed. Furthermore, IFN selectively induced apoptosis of USP6+ but not USP6- ES cells. Gene expression analysis confirmed that in USP6+ ES cells, IFN synergistically induced expression of numerous IFN-stimulated genes (ISGs), including the pro-apoptotic ligand TRAIL. CRISPR-mediated depletion of TRAIL completely abrogated IFN-induced death of USP6+ ES cells. In sum, these results identify USP6 as a potential novel biomarker that may predict sensitivity of ES to targeted IFN therapy. This abstract is also being presented as Poster B11. Citation Format: Ian Henrich, Rob Young, Laura Quick, Xiaoke Wang, Andre Oliveira, Margaret Chou. Ubiquitin-specific protease 6 (USP6) oncogene confers sensitivity of Ewing sarcoma to interferon cytotoxicity [abstract]. In: Proceedings of the AACR Conference on Advances in Sarcomas: From Basic Science to Clinical Translation; May 16-19, 2017; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(2_Suppl):Abstract nr PR08.
Donor-Site Morbidity and Functional Status following Medial Femoral Condyle Flap Harvest
Mehio, Ghassan, Morsy, Mohamed , Cayci, Cenk, Sabbagh, M. Diya , Moran, Steven L. , Carlsen, Brian T. , Shin, Alexander Y. , Bishop, Allen T.

Mayo Clinic

Plastic & Reconstructive Surgery | August 17, 2018 | Volume: 142 | Issue: 5 | Pages: 734e-741e

10.1097/prs.0000000000004886 | PMID 30119109 Get It

Background: The medial femoral condyle free vascularized bone flap is a valuable alternative to other types of vascularized bone grafts. The donor-site morbidity and functional outcomes after flap harvest have not been fully appreciated. The authors report the postoperative outcomes and analyze the impact of increasing the size of the flap on knee donor-site morbidity. Methods: A retrospective chart review of patients who underwent medial femoral condyle flap surgery between 2001 and 2012 at their institution was performed. The size of the flap was stratified, based on the largest dimension, into three groups. Demographics, outcomes, and complications related to the flap donor site were recorded and analyzed. Subsequently, functional status was assessed by administering a validated condition-specific measure. A univariate logistic regression analysis was performed, and results were analyzed. Results: A total of 75 patients were identified. Average age was 29.5 ± 15.2 years. Average follow-up time was 13 months. The overall complication rate was 18.6 percent. Paresthesia in the saphenous nerve distribution was the most common complication. Increasing the size of the flap resulted in a significant elevation in complication risk (p < 0.05). A total of 47 patients completed the Lower Extremity Functional Scale questionnaire. The average Lower Extremity Functional Scale score was 72.12 ± 14.18. Fifty-one percent (n = 24) scored 80 points, indicating a normal level of function on average. Conclusions: The medial femoral condyle flap has overall acceptable donor-site morbidity, with a good level of function postoperatively. Larger flaps are associated with a greater number of complications. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
Abstract 4241: Associations between perceived medical device-related radiation harm and adherence to mammography screening guidelines
Taparra, Kekoa , Pepin, Kay , Greenberg, Alexandra J.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 4241-4241

10.1158/1538-7445.am2018-4241 Get It

Abstract Introduction: Many forms of cancer screening involve imaging technologies utilizing radiation. Broad media coverage of radiation-related health risks may shape the public's perceptions of imaging-based cancer screening, such as mammography. In turn, this may impact patient outcomes by affecting cancer screening decisions. Our primary aim was to evaluate population differences in beliefs about medical radiation exposure in the United States and associations with mammography screening rates in women. Methods: We analyzed data from the National Cancer Institute's Health Information National Trends Survey (HINTS) 2012 administration. Bivariate and multivariate regression analyses were used to evaluate associations of sex, ethnicity, age, annual income, and education with perceptions of harm from medical test radiation exposure. Additional analyses evaluated the role of radiation perception on compliance with current mammography screening recommendations from the United States Preventive Services Task Force. Results: Approximately one-third of respondents indicated that they worried about medical imaging-related radiation exposure. Respondents who perceived medical imaging radiation as harmful to health were more likely to be female, be diagnosed with cancer, have less formal education, report lower socioeconomic status, and identify as an ethnic minority. Most female participants were not in compliance with current breast cancer screening recommendations (weighted percentage = 83.8%). Annual income (p = 0.042) and ethnicity (p = 0.0478) were two variables that were significantly associated with adherence to the recommended mammography screening paradigm. Women without health insurance were more likely to worry about medical imaging-related radiation (p=0.073). Neither health insurance (95%CI = 0.29, 4.99) nor excess worry about radiation exposure from medical imaging devices (95%CI=0.42, 1.89) predicted compliance to mammography screening, after adjusting for relevant sociodemographic variables. Conclusions: These results indicate that some populations may be more concerned about harm from medical device-related radiation than others. Identifying these populations may help improve future cancer patient outcomes by promoting targeted health interventions and communication strategies for these individuals. Women may be more likely to perceive medical imaging radiation exposure as harmful to health, however this alone could not account for why the majority of female respondents were not adhering to recommended mammograms screening guidelines. Future studies are needed to identify the major contributor to low breast cancer screening rates in the United States. Citation Format: Kekoa Taparra, Kay M. Pepin, Alexandra J. Greenberg-Worisek. Associations between perceived medical device-related radiation harm and adherence to mammography screening guidelines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4241.
Antiangiogenic Therapy in Colorectal Cancer
Mody, Kabir , Baldeo, Candice , Bekaii‐Saab, Tanios , Bekaii-Saab, Tanios S

Mayo Clinic

The Cancer Journal | August 17, 2018 | Volume: 24 | Issue: 4 | Pages: 165-170

10.1097/ppo.0000000000000328 | PMID 30119079 Get It

Abstract Colorectal carcinoma is the third most common cancer worldwide. Approximately 20% of patients with colorectal cancer will have metastatic disease at the time of initial diagnosis, and approximately 30% to 50% of patients with primary colon cancer will relapse and die of metastatic cancer. The 5-year survival rate of metastatic colorectal cancer remains disappointing at approximately 10%. Angiogenesis plays a significant role in tumor growth and metastasis in colorectal carcinoma. There are currently 4 US Food and Drug Administration–approved antiangiogenic agents for metastatic colorectal cancer. Bevacizumab is the only antiangiogenic agent approved by the US Food and Drug Administration for first-line treatment of metastatic colorectal cancer. Other antiangiogenic agents include ramucirumab, ziv-aflibercept, and regorafenib. We review the data supporting the use of antiangiogenics in this disease.
Endocrine Deficiency As a Function of Radiation Dose to the Hypothalamus and Pituitary in Pediatric and Young Adult Patients With Brain Tumors
Vatner, Ralph E. , Niemierko, Andrzej , Misra, Madhusmita , Weyman, Elizabeth A. , Goebel, Claire P., Ebb, David H. , Huang, Mary , Mahajan, Anita , Grosshans, David R. , Stanley, Takara L. , MacDonald, Shannon M. , Tarbell, Nancy J., Yock, Torunn I. , Jones, Robin M, Huang, Mary S, Stanley, Takara, Jones, Robin M., Paulino, Arnold C.

Mayo Clinic

Journal of Clinical Oncology | August 17, 2018 | Volume: 36 | Issue: 28 | Pages: 2854-2862

10.1200/jco.2018.78.1492 | PMID 30118397 Get It

Purpose There are sparse data defining the dose response of radiation therapy (RT) to the hypothalamus and pituitary in pediatric and young adult patients with brain tumors. We examined the correlation between RT dose to these structures and development of endocrine dysfunction in this population. Materials and Methods Dosimetric and clinical data were collected from children and young adults (< 26 years of age) with brain tumors treated with proton RT on three prospective studies (2003 to 2016). Deficiencies of growth hormone (GH), thyroid hormone, adrenocorticotropic hormone, and gonadotropins were determined clinically and serologically. Incidence of deficiency was estimated using the Kaplan-Meier method. Multivariate models were constructed accounting for radiation dose and age. Results Of 222 patients in the study, 189 were evaluable by actuarial analysis, with a median follow-up of 4.4 years (range, 0.1 to 13.3 years), with 31 patients (14%) excluded from actuarial analysis for having baseline hormone deficiency and two patients (0.9%) because of lack of follow-up. One hundred thirty patients (68.8%) with medulloblastoma were treated with craniospinal irradiation (CSI) and boost; most of the remaining patients (n = 56) received involved field RT, most commonly for ependymoma (13.8%; n = 26) and low-grade glioma (7.4%; n = 14). The 4-year actuarial rate of any hormone deficiency, growth hormone, thyroid hormone, adrenocorticotropic hormone, and gonadotropin deficiencies were 48.8%, 37.4%, 20.5%, 6.9%, and 4.1%, respectively. Age at start of RT, time interval since treatment, and median dose to the combined hypothalamus and pituitary were correlated with increased incidence of deficiency. Conclusion Median hypothalamic and pituitary radiation dose, younger age, and longer follow-up time were associated with increased rates of endocrinopathy in children and young adults treated with radiotherapy for brain tumors.
Estimating lung, breast, and effective dose from low‐dose lung cancer screening CT exams with tube current modulation across a range of patient sizes
Hardy, Anthony J. , Bostani, Maryam, McMillan, Kyle, Zankl, M. , Cagnon, Chris H., McCollough, Cynthia, McCollough, Cynthia H. , McNitt‐Gray, Michael F.

Mayo Clinic

Medical Physics | August 17, 2018 | Volume: 45 | Issue: 10 | Pages: 4667-4682

10.1002/mp.13131 | PMID 30118143 Get It

PurposeThe purpose of this study was to estimate the radiation dose to the lung and breast as well as the effective dose from tube current modulated (TCM) lung cancer screening (LCS) scans across a range of patient sizes.MethodsMonte Carlo (MC) methods were used to calculate lung, breast, and effective doses from a low‐dose LCS protocol for a 64‐slice CT that used TCM. Scanning parameters were from the protocols published by AAPM's Alliance for Quality CT. To determine lung, breast, and effective doses from lung cancer screening, eight GSF/ICRP voxelized phantom models with all radiosensitive organs identified were used to estimate lung, breast, and effective doses. Additionally, to extend the limited size range provided by the GSF/ICRP phantom models, 30 voxelized patient models of thoracic anatomy were generated from LCS patient data. For these patient models, lung and breast were semi‐automatically segmented. TCM schemes for each of the GSF/ICRP phantom models were generated using a validated method wherein tissue attenuation and scanner limitations were used to determine the TCM output as a function of table position and source angle. TCM schemes for voxelized patient models were extracted from the raw projection data. The water equivalent diameter, Dw, was used as the patient size descriptor. Dw was estimated for the GSF/ICRP models. For the thoracic patient models, Dw was extracted from the DICOM header of the CT localizer radiograph. MC simulations were performed using the TCM scheme for each model. Absolute organ doses were tallied and effective doses were calculated using ICRP 103 tissue weighting factors for the GSF/ICRP models. Metrics of scanner radiation output were determined based on each model's TCM scheme, including CTDIvol, dose length product (DLP), and CTDIvol, Low Att, a previously described regional metric of scanner output covering most of the lungs and breast. All lung and breast doses values were normalized by scan‐specific CTDIvol and CTDIvol, Low Att. Effective doses were normalized by scan‐specific CTDIvol and DLP. Absolute and normalized doses were reported as a function of Dw.ResultsLung doses normalized by CTDIvol, Low Att were modeled as an exponential relationship with respect to Dw with coefficients of determination (R2) of 0.80. Breast dose normalized by CTDIvol, Low Att was modeled with an exponential relationship to Dw with an R2 of 0.23. For all eight GSF/ICRP phantom models, the effective dose using TCM protocols was below 1.6 mSv. Effective doses showed some size dependence but when normalized by DLP demonstrated a constant behavior.ConclusionLung, breast, and effective doses from LCS CT exams with TCM were estimated with respect to patient size. Normalized lung dose can be reasonably estimated with a measure of a patient size such as Dw and regional metric of CTDIvol covering the thorax such as CTDIvol, Low Att, while normalized breast dose can also be estimated with a regional metric of CTDIvol but with a larger degree of variability than observed for lung. Effective dose normalized by DLP can be estimated with a constant multiplier.
Neuropilin‐1 maintains dimethylarginine dimethylaminohydrolase 1 expression in endothelial cells, and contributes to protection from angiotensin II–induced hypertension
Wang, Ying , Wang, Enfeng , Zhang, Yuebo , Madamsetty, Vijay Sagar , Ji, Baoan , Grande, Joseph P. , Misra, Sanjay , Madamsetty, Vijay S, Radisky, Derek C. , Misra, Sanjay , Madamsetty, Vijay S , Mukhopadhyay, Debabrata , Wang, Ying

Mayo Clinic

The FASEB Journal | August 17, 2018 | Volume: 33 | Issue: 1 | Pages: 494-500

10.1096/fj.201800499r | PMID 30118322 Get It

ABSTRACT Dimethylarginine dimethylaminohydrolases (DDAHs) are known to degrade asymmetric dimethylarginine, an endogenous inhibitor of NOS, and maintain vascular homeostasis; however, the regulatory pathways of DDAHs remain unclear. In this study, we aimed to define the role of transmembrane glycoprotein neuropilin‐1 (NRP1) in the expression of DDAHs and investigate the potential roles of NRP1 in regulation of blood pressure. Short hairpin RNA–mediated knockdown of NRP1 reduced the level and mRNA stability of DDAH1 but not DDAH2 in HUVECs, whereas overexpression of NRP1 increased the mRNA stability of DDAH1. Meanwhile, mesenteric arteries and lung vascular endothelial cells of tamoxifen‐inducible endothelial cell–specific NRP1 knockout mice exhibited decreased expression of DDAH1 and slightly increased expression of DDAH2. Mechanistically, the regulation of NRP1 on DDAH1 expression is mediated by a posttranscriptional mechanism involving miR‐219‐5p in HUVECs. Although the endothelial cell–specific NRP1 knockout mice did not exhibit any significant change in blood pressure at the basal level, they were more sensitive to low‐dose angiotensin II infusion–induced increases in blood pressure. Our results show that NRP1 is required for full expression of DDAH1 in endothelial cells and that NRP1 contributes to protection from low‐dose angiotensin II–induced increases in blood pressure.—Wang, Y., Wang, E., Zhang, Y., Madamsetty, V. S., Ji, B., Radisky, D. C., Grande, J. P., Misra, S., Mukhopadhyay, D. Neuropilin‐1 maintains dimethylarginine dimethylaminohydrolase 1 expression in endothelial cells, and contributes to protection from angiotensin II–induced hypertension. FASEB J. 33, 494–500 (2019). www.fasebj.org